DexCom, Inc. $DXCM Shares Purchased by AE Wealth Management LLC

AE Wealth Management LLC boosted its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 27.8% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 31,574 shares of the medical device company’s stock after purchasing an additional 6,873 shares during the quarter. AE Wealth Management LLC’s holdings in DexCom were worth $2,125,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Brighton Jones LLC grew its position in shares of DexCom by 257.7% during the fourth quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company’s stock worth $1,290,000 after buying an additional 11,946 shares in the last quarter. Integrated Wealth Concepts LLC boosted its stake in DexCom by 6.3% during the 1st quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company’s stock valued at $227,000 after acquiring an additional 196 shares during the last quarter. Empowered Funds LLC raised its stake in shares of DexCom by 5.4% in the 1st quarter. Empowered Funds LLC now owns 8,446 shares of the medical device company’s stock valued at $577,000 after purchasing an additional 436 shares in the last quarter. Focus Partners Wealth raised its stake in DexCom by 13.2% during the first quarter. Focus Partners Wealth now owns 7,218 shares of the medical device company’s stock valued at $493,000 after buying an additional 841 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in shares of DexCom by 6.8% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 190,693 shares of the medical device company’s stock valued at $16,646,000 after acquiring an additional 12,155 shares in the last quarter. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on DXCM shares. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of DexCom in a research report on Monday, December 29th. Truist Financial reissued a “buy” rating and issued a $82.00 price target (down previously from $94.00) on shares of DexCom in a research note on Monday, November 3rd. Leerink Partners reiterated an “outperform” rating and issued a $92.00 price objective on shares of DexCom in a report on Tuesday, December 16th. Wells Fargo & Company set a $93.00 target price on DexCom and gave the company an “overweight” rating in a research note on Friday, October 31st. Finally, Robert W. Baird set a $82.00 target price on shares of DexCom in a report on Friday, October 31st. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $86.30.

Insider Transactions at DexCom

In other news, Director Richard Alexander Collins sold 3,948 shares of the company’s stock in a transaction that occurred on Monday, November 10th. The shares were sold at an average price of $55.17, for a total transaction of $217,811.16. Following the transaction, the director directly owned 37,994 shares in the company, valued at approximately $2,096,128.98. This represents a 9.41% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Jacob Steven Leach acquired 18,200 shares of the firm’s stock in a transaction that occurred on Monday, November 10th. The shares were bought at an average cost of $55.04 per share, with a total value of $1,001,728.00. Following the completion of the purchase, the chief operating officer owned 331,697 shares of the company’s stock, valued at $18,256,602.88. This trade represents a 5.81% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last ninety days, insiders sold 7,866 shares of company stock valued at $448,177. Corporate insiders own 0.32% of the company’s stock.

DexCom Stock Performance

Shares of DXCM opened at $73.04 on Monday. The company has a quick ratio of 1.38, a current ratio of 1.56 and a debt-to-equity ratio of 0.45. The firm has a market cap of $28.49 billion, a price-to-earnings ratio of 40.58, a price-to-earnings-growth ratio of 1.31 and a beta of 1.49. The company’s fifty day moving average is $67.82 and its 200-day moving average is $70.67. DexCom, Inc. has a 12 month low of $54.11 and a 12 month high of $93.25.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, October 30th. The medical device company reported $0.61 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.57 by $0.04. DexCom had a net margin of 15.96% and a return on equity of 30.65%. The business had revenue of $1.21 billion for the quarter, compared to analyst estimates of $1.18 billion. During the same period last year, the business posted $0.45 EPS. DexCom’s revenue was up 21.6% compared to the same quarter last year. Equities analysts expect that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.